Olayinka Olaniyi, Ojimba Chiedozie, Alemu Brook, Olaolu Olalekan, Edomias Desta, Popoola Olusegun, Kallikkadan Jisha, Tumenta Terence, Gayam Vijay, Valbrun Leon, Olupona Tolu, Hershberger Jason
Department of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Integrated Health Sciences Program, School of Health Sciences, Western Carolina University, Cullowhee, NC, USA.
J Clin Med Res. 2020 Apr;12(4):243-250. doi: 10.14740/jocmr4110. Epub 2020 Mar 30.
Cannabis is the second most used recreational drug in the United States and one of the most used substances in patients with schizophrenia spectrum disorder (SSD). Unfortunately, the increased use is likely to continue as more states legalize recreational use of cannabis. Although the association between cannabis and schizophrenia has been studied extensively, the understanding of the relationship is still evolving. In this study, we sought to determine the prevalence and potential factors associated with cannabis use (CU) among inpatients with SSD at a community teaching hospital.
We performed a retrospective review of the electronic medical charts of patients discharged from the psychiatric unit of our hospital from July 1, 2017 through October 31, 2017. Patients were included in this study if: 1) They were ≥ 18 years old; 2) They had discharge diagnosis of SSD; and 3) They had urine drug testing performed. Pertinent sociodemographic and clinical variables, including substance use status and hospital length of stay (LOS), were abstracted. Univariate frequencies and summary statistics were performed. Odds ratios (ORs) were determined by logistic regression analysis of bivariate and multivariate analyses.
Three hundred sixty-five (52.2%) patients had a discharge diagnosis of SSD, and only 322 had urine toxicology result for cannabinoids and were included in analysis. Of the 322 patients, 41.5% (n = 133) screened positive for cannabinoids. Of the 133 patients, 78% were African American, 15% were Hispanic and 5% were White; 77% were male and the median age was 36 years. Bivariate analyses showed tobacco use (OR: 2.8, 95% confidence interval (CI): 1.7 - 4.6), alcohol use (OR: 3.4, 95% CI: 2.9 - 7.0), younger age (OR: 2.8, 95% CI: 1.8 - 4.5), male gender (OR: 2.9, 95% CI: 2.2 - 3.2), unemployment (OR: 3.91, 95% CI: 3.49 - 7.35), homelessness (OR: 3.18, 95% CI: 2.76 - 3.84) and LOS (OR: 3.46, 95% CI: 2.93 - 4.31) were significantly associated with CU. Result of multivariate analysis was similar to that found in bivariate analysis.
CU appears to be prevalent among patients with SSD. Clinicians and public health professionals are encouraged to understand the health implications of its use in patients with mental illness especially against the backdrop of current marijuana laws.
大麻是美国第二常用的消遣性毒品,也是精神分裂症谱系障碍(SSD)患者中最常用的物质之一。不幸的是,随着越来越多的州将大麻消遣性使用合法化,其使用量可能会继续增加。尽管大麻与精神分裂症之间的关联已得到广泛研究,但对两者关系的理解仍在不断发展。在本研究中,我们试图确定一家社区教学医院中SSD住院患者中大麻使用(CU)的患病率及相关潜在因素。
我们对2017年7月1日至2017年10月31日期间从我院精神科出院的患者的电子病历进行了回顾性研究。符合以下条件的患者纳入本研究:1)年龄≥18岁;2)出院诊断为SSD;3)进行了尿液药物检测。提取了相关的社会人口统计学和临床变量,包括物质使用状况和住院时间(LOS)。进行了单变量频率分析和汇总统计。通过二元和多变量分析的逻辑回归分析确定比值比(OR)。
365名(52.2%)患者出院诊断为SSD,只有322名患者有大麻素的尿液毒理学结果并纳入分析。在这322名患者中,41.5%(n = 133)大麻素筛查呈阳性。在这133名患者中,78%为非裔美国人,15%为西班牙裔人且5%为白人;77%为男性,中位年龄为36岁。二元分析显示,烟草使用(OR:2.8,95%置信区间(CI):1.7 - 4.6)、酒精使用(OR:3.4,95% CI:2.9 - 7.0)、较年轻年龄(OR:2.8,95% CI:1.8 - 4.5)、男性(OR:2.9,95% CI:2.2 - 3.2)、失业(OR:3.91,95% CI:3.49 - 7.35)、无家可归(OR:3.18,95% CI:2.76 - 3.84)和住院时间(OR:3.46,95% CI:2.93 - 4.31)与CU显著相关。多变量分析结果与二元分析结果相似。
CU在SSD患者中似乎很普遍。鼓励临床医生和公共卫生专业人员了解其在精神疾病患者中使用对健康的影响,尤其是在当前大麻法律的背景下。